JOURNAVX prescriptions exceeded 750,000, rising more than 40% sequentially. More than 1.6 million patients in the United States have been treated, indicating continued expansion of use in its launch market.
Key facts
Vertex JOURNAVX prescriptions exceeded 750,000, up more than 40% sequentially. source
Vertex JOURNAVX generated $58 million in Q3 2026 revenue, up 18% quarter over quarter. source
More than 1.6 million patients in the US had been treated with Vertex JOURNAVX. source